USA flag logo/image

An Official Website of the United States Government

Brain Injury During CPR Prevented by Vascular Nitroxide

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66699
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
NS043016
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
SYNZYME TECHNOLOGY, INC.
1 TECHNOLOGY DR, B-115 IRVINE, CA 92618-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Brain Injury During CPR Prevented by Vascular Nitroxide
Agency: HHS
Contract: 1R43NS043016-01A2
Award Amount: $100,004.00
 

Abstract:

DESCRIPTION (provided by applicant): The brain damage that frequently accompanies cardiac arrest and resuscitation is devastating. Fewer than 10% of cardiopulmonary resuscitation (CPR) attempts result in survival without brain damage when treatment occurs in pre-hospital or a non-special care hospital environment (Safar, 1993). We propose that a novel vascular-compartmentalized nitroxide, polynitroxyl albumin (PNA), which is an enzyme-mimic antioxidant, can reduce brain damage after CPR. We present preliminary results in a CPR model showing PNA attenuates CA1 hippocampal cell loss 7 days after cardiac compression and resuscitation in rats. Published results also support this premise. In a middle cerebral artery occlusion model of stroke, mice treated with PNA were significantly protected against neural damage. We propose to further establish the cerebral protective activity of PNA in a cardiac compression model of CPR. Our specific aims are: 1) to address quality assurance issues in PNA production and in vitro documentation of efficacy, and 2) to compare the impact of PNA, human serum albumin (HSA) and saline treatment on the structure and function of the hippocampus. The end-points for the second aim will include measures of pyramidal cell viability, NMDA receptor 1 immunoreactivity, and in vitro electrophysiology of hippocampal slices. This combined morphological and electrophysiological approach in a whole body ischemia model should further document the value of PNA as a potent neuroprotectant. Attainment of these goals will fulfill the feasibility requirement for further study of PNA in a Phase II SBIR grant, which will emphasize dose response, extended time course, neurological recovery and the therapeutic index of PNA.

Principal Investigator:

Carleton J. Hsia
9494531072
CHSIA@SYNZYME.COM

Business Contact:


7144531072
Small Business Information at Submission:

SYNZYME TECHNOLOGY, INC.
SYNZYME TECHNOLOGY, INC. 1 TECHNOLOGY DR, E-309 IRVINE, CA 92618

EIN/Tax ID: 330808054
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No